Last reviewed 2026-04-20 · How we verify

Neoadjuvant docetaxel + cyclophosphamide (neoadjuvant-docetaxel-cyclophosphamide)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Alopecia
• Diarrhoea
• Nausea
• Anaemia
• Neutropenia
• Leukopenia
• NAUSEA
• DIARRHOEA
• Fatigue
• ALOPECIA
• FATIGUE
• Asthenia

Key clinical trials

• Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy (NA)
• Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (PHASE2)
• A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer (PHASE2)
• A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (PHASE3)
• Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer (PHASE2)
• Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer (PHASE2)
• Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy (PHASE2)
• PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Neoadjuvant docetaxel + cyclophosphamide CI brief — competitive landscape report
• Neoadjuvant docetaxel + cyclophosphamide updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI